Biological variation and prognosis usefulness of new biomarkers in liver transplantation

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 6, 2013, Pages 1241-1249

  Miguel, Diego ^a   Prieto, Belén ^a   Álvarez, Francisco V ^a,b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Biological variation; Liver transplantation; MR proadrenomedullin

Indexed keywords

ATRIAL NATRIURETIC FACTOR; PREPROENDOTHELIN 1; PROADRENOMEDULLIN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD SAMPLING; FEMALE; GRAFT DYSFUNCTION; HEPATOBILIARY DISEASE; HEPATOPULMONARY SYNDROME; HEPATORENAL SYNDROME; HUMAN; INFECTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; OBSERVATIONAL STUDY; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STRESS; THROMBOSIS; VASCULAR DISEASE;

ADRENOMEDULLIN; ADULT; AGED; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKERS; ENDOTHELIN-1; FEMALE; HUMANS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84882327325     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0713     Document Type: Article

References (39)

1. Matesanz R, De La Rosa G. Liver transplantation: the Spanish experience. Digest Liver Dis Suppl 2009;3:75-81.
2. Russ PD, Elliot DE, Durham JD, Garg K, Wasch ME, Kam I. Liver transplantation complications. Available from: http://emedicine.com/radio/ topic883.htm#section. 2007.
3. Hickman PE, Potter JM, Pesce AJ. Clinical chemistry and post-liver-transplant monitoring. Clin Chem 1997;43:1546-54.
4. Kunz D, Pross M, Konig W, Lippert H, Manger T. Diagnostic relevance of procalcitonin, IL-6 and cellular immune status in the early phase after liver transplantation. Transplant Proc 1998;30:2398-9.
5. Moreno R, Berenguer M. Post-liver transplantation medical complications. Ann Hepatol 2006;5:77-85.
6. Warle MC, Metselaar HJ, Hop WC, Gyssens IC, Kap M, Kwekkeboom J, et al. Early differentiation between rejection and infection in liver transplant patients by serum and biliary cytokine patterns. Transplantation 2003;75:146-51.
7. Zhao X, Koshiba T, Fujimoto Y, Pirenne J, Yoshizawa A, Ito T, et al. Proinflammatory and antiinflammatory cytokine production during ischemia-reperfusion injury in a case of identical twin living donor liver transplantation using no immunosuppression. Transplant Proc 2005;37:392-4.
8. Santiago F, Bueno P, Olmedo C, Comino A, Hassan L, Ferron-Celma I, et al. Time course of intraoperative cytokine levels in liver transplant recipients. Transplant Proc 2006;38:2492-4.
9. Oberhoffer M, Vogelsang H, Jager L, Reinhart K. Katacalcin and calcitonin immunoreactivity in different types of leukocytes indicate intracellular procalcitonin content. J Crit Care 1999;14:29-33.
10. Chieveley-Williams S, Hamilton-Davies C. The role of the gut in major surgical postoperative morbidity. Int Anesthesiol Clin 1999;37:81-110.
11. Hammer S, Meisner F, Hammer C, Seidel D. Use of procalcitonin as indicator of nonviral infections in transplantation and related immunologic diseases. Transplant Rev 2000;14:52-63.
12. Kretzschmar M, Kruger A, Schirrmeister W. Procalcitonin following elective partial liver resection-origin from the liver ? Acta Anaesthesiol Scand 2001;45:1162-7.
13. Matwiyoff GN, Prahl JD, Miller RJ, Carmichael JJ, Amundson DE, Seda G, et al. Immune regulation of procalcitonin: a biomarker and mediator of infection. Inflamm Res 2012;61:401-9.
14. Staehler M, Hammer C, Meiser B, Reichart B. Procalcitonin: a new marker for differential diagnosis of acute rejection and bacterial infection in heart transplantation. Transplant Proc 1997;29:584-5.
15. Hammer S, Meisner F, Dirschedl P, Hobel G, Fraunberger P, Meiser B, et al. Procalcitonin: a new marker for diagnosis of acute rejection and bacterial infection in patients after heart and lung transplantation. Transpl Immunol 1998;6:235-41.
16. Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Müller B. Mid-regional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 2005;9:816-24.
17. Miguel D, Prieto B, Costa M, Coto D, Álvarez FV. Cord blood plasma reference intervals for potential sepsis markers: pro-adrenomedullin, pro-endothelin and pro-atrial natriuretic peptide. Clin Biochem 2011;44:337-41.
18. Fraser CG. Biological variation: from principles to practice. Washington DC: AACC Press, 2001.
19. Prieto B, Llorente E, González-Pinto I, Álvarez FV. Plasma procalcitonin measured by time-resolved amplified cryptate emission (TRACE) in liver transplant patients. A prognosis marker of early infectious and non-infectious postoperative complications. Clin Chem Lab Med 2008;46:660-6.
20. Fábrega E, Crespo J, Casfont F, De La Peña J, García-Unzueta MT, Amado JÁ, et al. Adrenomedullin in liver transplantation and its relationship with vascular complications. Liver Transpl Surg 1999;5:485-90.
21. Nagasue N, Dhar DK, Yamanoi A, Emi Y, Udagawa J, Yamamoto A, et al. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology 2000;31:1107-14.
22. Carini R, De Cesaris MG, Splendore R, Domenicotti C, Nitti MP, Pronzato MA, et al. Mechanisms of hepatocyte protection against hypoxic injury by atrial natriuretic peptide. Hepatology 2003;37:277-85.
23. Lainscak M, Haehling S, Anker SD. Natriuretic peptides and other biomarkers in chronic heart failure: from BNP, NT-proBNP, and MR-proANP to routine biochemical markers. Int J Cardiol 2009;132:303-11.
24. Von HS, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, et al. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. J Am Coll Cardiol 2007;50:1973-80.
25. Fraser CG, Harris EK. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 1989;27:409-37.
26. Ricós C, Alvarez V, Cava F, García-Lario JV, Hernández A, Jiménez CV, et al. Desirable Specifications for imprecision, inaccuracy, and total allowable error, calculated from data on within-subject and between-subject biologic variation. Available from: http://www.westgard.com/biodatabase1.htm. Accessed 13 June, 2012.
27. Ordoñez-Llanos J, Collinson PO, Christenson RH. Amino-terminal pro-B-type natriuretic peptide: analytic considerations. Am J Cardiol 2008;101:9-15.
28. Wu AH. Serial testing of B-type natriuretic peptide and NT-proBNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006;152:828-34.
29. Bruins S, Fokkema MR, Romer JW, Dejongste MJ, Van Der Dijs FP, Van Den Ouweland JM, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-8.
30. Avello N, Prieto B, Díaz-Molina B, Rodríguez-Lambert JL, Álvarez F V. Clinical utility of NT-proBNP levels in late heart transplantation patients. Clin Chim Acta 2010;411:161-6.
31. Neuhold S, Huelsmann M, Strunk G, Struck J, Adlbrecht C, Gouya G, et al. Prognostic value of emerging neurohormones in chronic heart failure during optimization of heart failure-specific therapy. Clin Chem 2010;56:121-6.
32. Brauner JS, Rohde LE, Clausell N. Circulating endothelin-1 and tumor necrosis factor-alpha: early predictors of mortality in patients with septic shock. Intens Care Med 2000;26:305-13.
33. Morgenthaler NG, Struck J, Christ-Crain M, Bergmann A, Muller B. Pro-atrial natriuretic peptide is a prognostic marker in sepsis, similar to the APACHE II score: an observational study. Crit Care 2005;9:R37-45.
34. Suverbiola B, Castellanos-Ortega A, Llorca J, Ortiz F, Iglesias D, Prieto B. Prognostic value of proadrenomedullin in severe sepsis and septic shock patients with community-acquired pneumonia. Swiss Med Wkly 2012;142:w13542.
35. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br Med J 2005;330:625.
36. Schnabel R, Lubos E, Rupprecht HJ, Espínola-Klein C, Bickel C, Lackner KJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: results from the Athero Gene study. J Am Coll Cardiol 2006;47:552-8.
37. McKie PM, Rodeheffer RJ, Cataliotti A, Martin FL, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006;47:874-80.
38. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnosis accuracy of B-type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 2005;91:606-12.
39. Januzzi JL Jr., Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95:948-54.